lunes, 7 de marzo de 2016

Ewing Sarcoma Treatment (PDQ)—Health Professional Version - National Cancer Institute

Ewing Sarcoma Treatment (PDQ)—Health Professional Version - National Cancer Institute

National Cancer Institute

Ewing Sarcoma Treatment–Health Professional Version (PDQ®)


Changes to This Summary (03/03/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that CDKN2A deletions were noted in 12% to 22% of cases.
Added Figure 1 depicting a comprehensive profile of the genetic abnormalities in Ewing sarcoma, which highlights the frequency of chromosome 8 gain, the co-occurrence of chromosome 1q gain and chromosome 16q loss, the mutual exclusivity of CDKN2A deletion andSTAG2 mutation, and the relative paucity of recurrent single nucleotide variants for Ewing sarcoma.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: March 3, 2016

No hay comentarios:

Publicar un comentario